Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug–Drug Interactions

Venetoclax (ABT-199) represents a specific B-cell lymphoma 2 (Bcl-2) inhibitor that is currently under development for the treatment of lymphoid malignancies. So far, there is no published information on its interaction potential with important drug metabolizing enzymes and drug transporters, or its...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiss, Johanna, Gajek, Thomas, Köhler, Bruno Christian, Haefeli, Walter Emil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810081/
https://www.ncbi.nlm.nih.gov/pubmed/26927160
http://dx.doi.org/10.3390/pharmaceutics8010005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810081/
https://www.ncbi.nlm.nih.gov/pubmed/26927160
http://dx.doi.org/10.3390/pharmaceutics8010005

Ejemplares similares